Skip to main content
. 2020 Dec 17;4(24):6283–6290. doi: 10.1182/bloodadvances.2020003418

Figure 1.

Figure 1.

Outcomes in different time periods of adult patients with hematologic malignancy who underwent first allo-SCT with a transplant from a matched family donor. The periods were separated into decades (A,C-D), and NRM was separated into 5-year periods (B). NRM (A-B), overall survival (C), and progression-free survival (D).